Drug Search Results
More Filters [+]

INO-5150

Alternative Names: ino-5150, ino5150, ino 5150
Latest Update: 2020-01-21
Latest Update Note: News Article

Product Description

DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02514213)

Mechanisms of Action: DNA Immuno

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INO-5150

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PCa-001

P1

Completed

Prostate Cancer

2017-12-12

Recent News Events